Actions of Pharmaceutical Syndax (NASDAQ:SNDX) were flat in the aftermarket after the company released its fourth quarter results.
Earnings per share increased 0.00% year-over-year to ($ 0.44), beating the estimate of ($ 0.49).
Revenue of $ 380,000 unchanged 0.00% from same period last year, exceeding estimate of $ 200,000.
Syndax forecasts R&D spending in the first quarter of 2021 of $ 25-30 million; Total operating expenses of $ 30M to $ 35M
Syndax Pharmaceuticals Sees $ 90 Million to $ 100 Million in R&D Expenditures for Fiscal 2021; Total operating expenses for fiscal 2021 from $ 110M to $ 120M
Conference call details
Date: March 08, 2021
Time: 4:30 p.m.
Webcast URL AND: https://edge.media-server.com/mmc/p/wdaqmgg3
Recent stock market performance
52 week high: $ 27.85
The company’s 52-week low was $ 6.88
Price action in the last quarter: up 22.96%
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidates are entinostat, which has direct effects on cancer cells and regulatory immune cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response to tumors that have shown sensitivity to immunotherapy. The group’s commercial activity is carried out mainly through the region of the United States.
See more Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.